Intra-Cellular Therapies (ITCI) reported a Q4 net loss Friday of $0.16 per diluted share, compared with a loss of $0.29 a year earlier.
Analysts polled by FactSet expected a loss of $0.07.
Total revenue for the quarter ended Dec. 31 was $199.2 million, up from $132.1 million a year earlier.
Analysts surveyed by FactSet expected $193.4 million.
Intra-Cellular shares were 0.8% higher in recent trading.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。